Yasheng Pharmaceutical will make its debut at the 2021 Service Trade Fair with a number of "Chinese Wise Drugs", demonstrating its global innovation capabilities

Ascent Pharmaceuticals (6855.

Yasheng Pharmaceutical is one of the first biopharmaceutical companies that signed a contract to set up a new health and health service exhibition area at the Service Trade Fair.

As one of the earliest innovative drug companies focusing on original innovation, Yasheng Pharmaceuticals has always

Work together to improve the accessibility of high-quality medical services and promote the development of China's health service industry

At present, the original class 1 new drug HQP1351, which is used to treat patients with drug-resistant CML, has been submitted for new drug marketing in China, and it has been included in the priority review and breakthrough treatment varieties

At the Service Trade Fair, an important exhibition that spreads ideas, connects supply and demand, shares business opportunities, and promotes development in the field of international service trade, Yasheng Pharmaceutical will sign a series of strategic cooperation agreements and agreements with many partners such as genetic testing companies and Internet medical companies.

As one of the earliest leading innovative drug companies in the global market, Yasheng Pharmaceuticals has been based in China and facing the world since its establishment, and looks forward to bringing Chinese original and world-leading innovative drugs to the world, not only helping to improve China’s health services The development of the industry also meets the needs of the global health service industry

During the service trade fair, Dr.

Dr.

This year is the first show of Yasheng Pharmaceutical's Service Trade Fair, and we are very happy to participate in this global event

About Yasheng Pharmaceutical

Yasheng Pharmaceutical is a biomedical company based in China and facing the world.

Ascent Pharmaceuticals has a self-constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug development in the apoptosis pathway in the world

Relying on strong R&D capabilities, Yasheng Pharmaceuticals has deployed intellectual property rights worldwide, and has cooperated with leading biotechnology and pharmaceutical companies such as UNITY, MD Anderson, Mayo Medical Center, Dana-Farber Cancer Institute, Merck, AstraZeneca, etc.
Companies and academic institutions have reached a global partnership
.
The company has established an international talent team with rich experience in original innovative drug research and development and clinical development.
At the same time, the company is building a late-stage commercial production and marketing team with high standards
.
Yasheng Pharmaceutical will continue to improve its research and development capabilities, accelerate the progress of the clinical development of the company's product pipeline, and truly implement the mission of "solving the unmet clinical needs of patients in China and even the world" to benefit more patients
.

Forward-looking statement

The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article
.
Except as required by law, we have no obligation to update or publicly revise any forward-looking statements and unexpected events after the date of forward-looking statements, regardless of whether new information, future events or other circumstances appear
.
Please read this article carefully and understand that our actual future results or performance may differ materially from expectations
.
All statements in this article are made on the date of publication of this article and may change due to future developments
.